» Articles » PMID: 23759423

Serum Biomarkers and Transient Elastography As Predictors of Advanced Liver Fibrosis in a United States Cohort: the Boston Children's Hospital Experience

Overview
Journal J Pediatr
Specialty Pediatrics
Date 2013 Jun 14
PMID 23759423
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate and compare the ability of serum hyaluronic acid (HA) and human cartilage glycoprotein-39 (YKL-40) values, as well as transient elastography (TE) findings, to predict advanced hepatic fibrosis in a cohort from a single pediatric center.

Study Design: Subjects who underwent liver biopsy analysis within 12 months before enrollment were eligible for this prospective study. HA and YKL-40 measurements were obtained within 1 month of TE. A METAVIR score of F3 or F4 was considered to indicate advanced fibrosis.

Results: A total of 128 patients (51% males) aged 1.4 months to 27.6 years (22% aged <2 years) were enrolled. Thirty-one subjects had data on only HA and YKL-40 measurements, and 97 subjects had data on both blood tests and TE. For the prediction of advanced fibrosis, the area under the receiver operating characteristic curve (AUC) values were 0.83 for TE, 0.72 for HA, and 0.52 for YKL-40. The AUC of 0.83 for TE was statistically significantly greater than the AUCs for HA (P = .03) and YKL-40 (P < .0001). Optimal cutpoints for predicting F3-F4 fibrosis were 8.6 kPa for TE (P < .0001), 43 ng/mL for HA (P < .0001), and 26.2 ng/mL for YKL-40 (P = .85). The combination of TE and HA was not better than TE alone for predicting advanced fibrosis (P = .15).

Conclusion: In this study, which evaluated TE, HA, and YKL-40 to predict liver fibrosis in children in the US, YKL-40 had no predictive value and TE was superior to HA, but the addition of HA did not improve the performance of TE. Our data suggest that TE and HA may be useful noninvasive tools for assessing liver fibrosis in children.

Citing Articles

KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.

Kim M, Han J, An J, Kim B, Jin Y, Kim S Clin Mol Hepatol. 2024; 30(Suppl):S5-S105.

PMID: 39159947 PMC: 11493350. DOI: 10.3350/cmh.2024.0506.


Longitudinal controlled attenuation parameter and liver stiffness in children with and without perinatal HIV infection in South Africa.

Rose P, Davies C, Cotton M, Otwombe K, Browne S, Vaida F AIDS. 2024; 38(11):1638-1647.

PMID: 38905492 PMC: 11317452. DOI: 10.1097/QAD.0000000000003964.


Analysis of the mediating role of BMI in associations of different folate forms with hepatic steatosis and liver fibrosis in adolescents in the USA: results from the NHANES 2017-2018.

Wen J, Fei Y, Yuan L, Li K, Xu Q, Cao X Front Endocrinol (Lausanne). 2023; 14:1273580.

PMID: 38116318 PMC: 10728716. DOI: 10.3389/fendo.2023.1273580.


Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges.

Hegarty R, Kyrana E, Fitzpatrick E, Dhawan A Ther Adv Endocrinol Metab. 2023; 14:20420188231160388.

PMID: 36968656 PMC: 10034351. DOI: 10.1177/20420188231160388.


Liver fibrosis in children: a comprehensive review of mechanisms, diagnosis, and therapy.

Ozdogan E, Arikan C Clin Exp Pediatr. 2022; 66(3):110-124.

PMID: 36550776 PMC: 9989719. DOI: 10.3345/cep.2022.00367.